After treatment withdrawal, 58.3% of patients with ankylosing spondylitis (AS) had relapsed. Half of the relapses appeared within 6 months.
Some recent data have indicated that it is feasible to reduce the dose of anti—tumor necrosis factor (anti-TNF) therapies in treating spondyloarthritis indications like ankylosing spondylitis (AS). In some cases, patients may stop biologic treatment entirely if they achieve sustained clinical remission, though data do not exist to support such a strategy.
One recent study sought to determine how long patients with AS in persistent clinical remission remained free of disease flares after withdrawing the anti-TNF infliximab, and it found that a majority of patients had clinical relapse within a year.
The multicenter, prospective, observational study included 36 Spanish patients with AS who had received infliximab as a first-line anti-TNF agent and who had been in remission for more than 6 months. Infliximab was withdrawn from these patients, and they were assessed every 6 to 8 weeks for 12 months. Clinical relapse was defined as a Bath Ankylosing Spondylitis Disease Activity Index score of 4 or higher. Among patients who relapsed, infliximab was reintroduced without an induction phase.
After treatment withdrawal, 12 (33.3%) of the patients remained free of clinical relapse, while 21 (58.3%) had relapsed and 3 patients were lost to follow-up. Half of the relapses appeared within 6 months of the anti-TNF withdrawal.
In the 21 patients who relapsed, infliximab was reintroduced, and 11 patients (52%) regained clinical remission. However, 10 patients (48%) did not regain remission. Among this group, 7 patients had a good clinical response, but in 3 patients, the reintroduced infliximab was ineffective, and the patients had to be cycled to a different anti-TNF agent altogether. No important adverse events were noted with the reintroduction of the drug.
According to the authors, this is the first study to show that, in a majority of patients with AS, withdrawal of infliximab was linked with relapse within 12 months. While reintroduction of infliximab was safe, many patients did not regain remission, and others had loss of efficacy.
While the study was limited by its small sample size, “Overall, the results we reported here suggest that the decision to withdraw treatment should be taken with considerable caution, and it seems unreasonable to propose withdrawal as an objective of the treatment strategy, at least at present, in the absence of any objective predictive factors of persistent clinical remission after treatment withdrawal,” write the authors.
Reference
Moreno M, Gratacós J, Torrente-Segarra T, et al. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results form the RIMINEA study. Arthritis Res Ther. 2019;21:88. doi: 10.1186/s13075-019-1873-3.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.